Overview of the BioE3 Policy Implementation The BioE3 Policy has been approved by the Cabinet and is being executed jointly by the DBT and its public‑sector enterprise BIRAC . The thrust is on high‑performance biomanufacturing, shared infrastructure and start‑up enablement across sectors such as bio‑chemicals, APIs, smart proteins, climate‑resilient agriculture and marine biotechnology. Key Developments Launch of India’s first Biofoundry Network across 8 academic institutions, providing a national platform for scale‑up. Establishment of 11 Biomanufacturing Platforms that support start‑ups, SMEs and academia in pilot and pre‑commercial scale‑up. Introduction of three tiered funding schemes: BIG , SEED and LEAP . Creation of RAPA to streamline regulatory queries through the FIRST Hub and REFINE programme. Expansion of incubation ecosystem: 94 BioNEST and E‑YUVA centres across 25 states, supporting >3,000 startups and students. Important Facts & Figures BIG has funded >1,000 projects, generated 200+ products, 800+ IP assets and attracted >₹3,500 crore follow‑on funding. SEED has backed 153 startups, creating 300+ IP assets and mobilising >₹1,162 crore. LEAP has supported 62 firms, leading to 150+ IP assets and >₹893 crore follow‑on investment. Collectively, the schemes have created roughly 7,300 jobs and contributed to a biotech sector that, per the India BioEconomy Report 2025 , employs 3.5 million people and hosts >10,000 startups. UPSC Relevance The BioE3 rollout illustrates how India is using targeted policy, public‑private partnership and financial incentives to build a strategic industry. Aspirants should link this to: India’s Make in India thrust and self‑reliance (Atmanirbhar Bharat) in high‑technology sectors. Employment generation and skill development under GS3 (Economic Growth) and GS4 (Ethics – inclusive growth). Regulatory reforms and single‑window clearances, relevant for GS3 questions on governance and ease of doing business. Science‑technology policy formulation and implementation, a recurring theme in GS3 and GS1 (Science & Tech History). Way Forward To realise the $300 bn target, the government must: Strengthen linkages between biofoundries and industry to ensure technology transfer. Expand the equity‑fund pipeline (e.g., AcE Fund) to bridge the “Valley of Death”. Enhance regulatory capacity through RAPA, ensuring faster approvals for biosimilars, cell‑gene therapies and marine biotech. Promote export‑oriented biomanufacturing to reduce import dependence on enzymes, APIs and bioplastics. Effective monitoring, transparent grant evaluation and periodic impact assessment will be crucial for sustaining momentum and delivering the envisioned bio‑economy benefits.